Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 and Retifanlimab in Advanced Merkel Cell Carcinoma
NCT07472322Phase 2Not yet recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2026
- Primary completion
- May 2031
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of inqovi, retifanlimab in Merkel cell carcinoma (MCC), sponsored by University of Wisconsin–Madison. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
inqoviretifanlimab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT07472322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07472322.